Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


1.		Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				#33 NCT00211198

Last Modified: 2/1/1996


2.		Phase III Randomized, Double-Blind Study of Two Doses of the IL-2 Receptor-Targeted Cytotoxin DAB389-IL2 for Recurrent or Persistent Cutaneous T-Cell Lymphoma (Summary Last Modified 02/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Pharmaceutical / Industry				SERAGEN-93-04-10 NCI-V95-0738

Last Modified: 3/7/2008 First Published: 12/1/1998


3.		Phase II Study of Denileukin Diftitox in Patients With Previously Treated Stage I, II, III, or IV Low- or Intermediate-Grade B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				E-1497 NCT00003615, E1497

Last Modified: 11/1/2001 First Published: 10/1/2000


4.		Phase II Study of Dexamethasone Followed By Denileukin Diftitox in Patients With Persistent or Recurrent Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				LIGAND-L4389-MR-9901 NCI-V00-1614, NCT00006345

Last Modified: 2/1/2002 First Published: 11/1/2001


5.		Phase II Study of Denileukin Diftitox in Patients With Stages I-IV Low- or Intermediate-Grade B-Cell Non-Hodgkin's Lymphoma (Summary Last Modified 02/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				PHARMATECH-LP-ONT-BL LIGAND-PHARMATECH-LP-ONT-BL, PHARMATECH-20002024, NCT00026429

Last Modified: 7/31/2007 First Published: 4/23/2004


6.		Phase II Study of Denileukin Diftitox in Patients With Metastatic Melanoma or Metastatic Kidney Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-04-C-0134 NCT00082914

Last Modified: 5/12/2006 First Published: 4/23/2004


7.		Phase II Study of Denileukin Diftitox in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				CCCWFU-27102 CCCWFU-BG02-331, LIGAND-CCCWFU-27102, NCT00082940


8.		A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				#35 NCT00211185


9.		A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				#123 NCT00211276


10.		Treatment for Acute Graft-Versus-Host Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				10 and over				NCI, NHLBI				285 BMT CTN 0302, U01 HL069294-05, NCT00224874

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute